Xenikos secures $30m in Series B Financing

Xenikos secures $30m in Series B Financing

18 May 2018

Congratulations to our client Xenikos who has raised $30 million from Series B financing.

Dutch company Xenikos are a clinical stage biopharmaceutical company currently developing a novel therapy for treating acute graft-versus-host disease (aGVHD).

The funding will be used to advance the development of Xenikos’ lead compound, T-Guard®. This includes conducting clinical Phase 3 trials for its treatment of aGVHD, a complication of stem cell transplants.

Medicxi and RA Capital Management, two new investors, participated in the financing round.

Read the full press release.

Chris Casley, partner in our life sciences patent team, and Sean Jauss, partner in our legal team, works with Xenikos on their IP portfolio.